As a group, analysts expect that BioMarin Pharmaceutical Inc. will post 1.06 earnings per share for the current year.

Source: https://www.etfdailynews.com/2023/05/27/raymond-james-financial-services-advisors-inc-sells-29955-shares-of-biomarin-pharmaceutical-inc-nasdaqbmrn/

Avian Securities downgraded BioMarin Pharmaceutical to a “market perform” rating in a research report on Wednesday, February 22nd.

Source: https://www.etfdailynews.com/2023/03/02/biomarin-pharmaceutical-nasdaqbmrn-price-target-cut-to-74-00-by-analysts-at-wedbush/

BioMarin Pharmaceutical () last issued its earnings results on Monday, July 31st.

Source: https://www.dailypolitical.com/2023/09/03/biomarin-pharmaceutical-inc-nasdaqbmrn-shares-bought-by-panagora-asset-management-inc.html

Caprock Group LLC lifted its holdings in BioMarin Pharmaceutical by 6.1% in the 1st quarter.

Source: https://www.americanbankingnews.com/2023/07/13/biomarin-pharmaceutical-inc-nasdaqbmrn-stock-position-decreased-by-first-national-trust-co.html

Finally, MML Investors Services LLC lifted its stake in BioMarin Pharmaceutical by 2.9% during the third quarter.

Source: https://www.etfdailynews.com/2023/03/21/biomarin-pharmaceutical-inc-nasdaqbmrn-shares-sold-by-foundations-investment-advisors-llc/

Finally, Sanford C. Bernstein assumed coverage on shares of BioMarin Pharmaceutical in a research note on Tuesday, March 21st.

Source: https://www.etfdailynews.com/2023/04/30/biomarin-pharmaceutical-inc-nasdaqbmrn-stock-position-reduced-by-janney-montgomery-scott-llc/

Finally, Two Sigma Advisers LP raised its holdings in BioMarin Pharmaceutical by 54.2% in the third quarter.

Source: https://www.etfdailynews.com/2023/07/01/biomarin-pharmaceutical-nasdaqbmrn-price-target-increased-to-73-00-by-analysts-at-wedbush/

From a strategic and operational standpoint, some investors appear to be underwhelmed with BioMarin.

Source: https://investorplace.com/2023/11/bmrn-stock-jumps-12-as-activist-elliott-targets-biomarin-pharmaceuticals/

Grey Fox Wealth Advisors LLC acquired a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $31,000.

Source: https://www.dailypolitical.com/2023/08/04/biomarin-pharmaceutical-nasdaqbmrn-price-target-lowered-to-70-00-at-wedbush.html

Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of BioMarin Pharmaceutical Inc. () by 1.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).

Source: https://www.dailypolitical.com/2023/11/12/mitsubishi-ufj-trust-banking-corp-has-15-84-million-stock-holdings-in-biomarin-pharmaceutical-inc-nasdaqbmrn.html

Morgan Stanley raised their price target on BioMarin Pharmaceutical from $111.00 to $113.00 and gave the company an “overweight” rating in a report on Thursday, October 27th.

Source: https://www.etfdailynews.com/2023/01/11/biomarin-pharmaceutical-nasdaqbmrn-hits-new-52-week-high-after-analyst-upgrade/

Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.

Source: https://www.prnewswire.com/news-releases/germany-cell-and-gene-therapy-market---focused-insights-2023-2028-sector-to-reach-3-44-billion-by-2028-at-a-40-cagr-301784069.html

Piper Sandler dropped their target price on shares of BioMarin Pharmaceutical from $125.00 to $115.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd.

Source: https://www.americanbankingnews.com/2023/11/30/dimensional-fund-advisors-lp-boosts-stake-in-biomarin-pharmaceutical-inc-nasdaqbmrn.html

Quadrant Capital Group LLC lifted its position in BioMarin Pharmaceutical by 188.6% during the second quarter.

Source: https://www.americanbankingnews.com/2023/04/10/biomarin-pharmaceutical-inc-nasdaqbmrn-receives-118-58-consensus-price-target-from-brokerages.html